Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofov...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrobial agents and chemotherapy 2021-01, Vol.65 (1)
Hauptverfasser: Calcagno, Andrea, Dal Conte, Ivano, Cattaneo, Dario, Testi, Roberto, Mistrangelo, Massimiliano, Gervasoni, Cristina, de Nicolò, Amedeo, Bonora, Stefano, D'Avolio, Antonio, Di Perri, Giovanni
Format: Artikel
Sprache:eng
Schlagworte:
Antiviral Agents
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page
container_title Antimicrobial agents and chemotherapy
container_volume 65
creator Calcagno, Andrea
Dal Conte, Ivano
Cattaneo, Dario
Testi, Roberto
Mistrangelo, Massimiliano
Gervasoni, Cristina
de Nicolò, Amedeo
Bonora, Stefano
D'Avolio, Antonio
Di Perri, Giovanni
description Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.
doi_str_mv 10.1128/AAC.01902-20
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7927807</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2454651953</sourcerecordid><originalsourceid>FETCH-LOGICAL-a418t-ffa91d5c989a2f9383372a09f71263811f4a956b98287505b30db481458908a3</originalsourceid><addsrcrecordid>eNp1kc1LxDAQxYMoun7cPEuOClYnSdMmF2FZdVdYcJHFa8h2UzfSNjVp_fjvja6KHjwNYX55M28eQocEzgih4nw4HJ0BkUATChtoQECKJOMy20QDgCxLUgHpDtoN4RHim0vYRjuMEchoDgNUT90LnpvGle7ZejyrdKg1vnptXei9wbbBk5t7fOt1hWfeJOa7MfOuXb1V-tUGfGcK21rTdAG_2G6Fxzp03tmmM6GzTfx5aYPzS-PDPtoqdRXMwVfdQ_Prq_lokkxvxzej4TTRKRFdUpZakiUvpJCalpIJxnKqQZY5oRkThJSpljxbSEFFzoEvGCwXqSApFxKEZnvoYi3b9ovaLIu4WjSgWm9r7d-U01b97TR2pR7cs8olzQXkUeD4S8C7pz7aULUNhakq3RjXB0VTnmacSM4ierpGC-9C8Kb8GUNAfQSkYkDqMyBFIeInazzemapH1_t4oPAfe_Tbxo_wd3rsHUc2mR4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2454651953</pqid></control><display><type>article</type><title>Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Calcagno, Andrea ; Dal Conte, Ivano ; Cattaneo, Dario ; Testi, Roberto ; Mistrangelo, Massimiliano ; Gervasoni, Cristina ; de Nicolò, Amedeo ; Bonora, Stefano ; D'Avolio, Antonio ; Di Perri, Giovanni</creator><creatorcontrib>Calcagno, Andrea ; Dal Conte, Ivano ; Cattaneo, Dario ; Testi, Roberto ; Mistrangelo, Massimiliano ; Gervasoni, Cristina ; de Nicolò, Amedeo ; Bonora, Stefano ; D'Avolio, Antonio ; Di Perri, Giovanni</creatorcontrib><description>Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.01902-20</identifier><identifier>PMID: 33106270</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Antiviral Agents</subject><ispartof>Antimicrobial agents and chemotherapy, 2021-01, Vol.65 (1)</ispartof><rights>Copyright © 2020 American Society for Microbiology.</rights><rights>Copyright © 2020 American Society for Microbiology. 2020 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a418t-ffa91d5c989a2f9383372a09f71263811f4a956b98287505b30db481458908a3</citedby><cites>FETCH-LOGICAL-a418t-ffa91d5c989a2f9383372a09f71263811f4a956b98287505b30db481458908a3</cites><orcidid>0000-0003-2534-8815 ; 0000-0002-1321-4126</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927807/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927807/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33106270$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Calcagno, Andrea</creatorcontrib><creatorcontrib>Dal Conte, Ivano</creatorcontrib><creatorcontrib>Cattaneo, Dario</creatorcontrib><creatorcontrib>Testi, Roberto</creatorcontrib><creatorcontrib>Mistrangelo, Massimiliano</creatorcontrib><creatorcontrib>Gervasoni, Cristina</creatorcontrib><creatorcontrib>de Nicolò, Amedeo</creatorcontrib><creatorcontrib>Bonora, Stefano</creatorcontrib><creatorcontrib>D'Avolio, Antonio</creatorcontrib><creatorcontrib>Di Perri, Giovanni</creatorcontrib><title>Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description>Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.</description><subject>Antiviral Agents</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kc1LxDAQxYMoun7cPEuOClYnSdMmF2FZdVdYcJHFa8h2UzfSNjVp_fjvja6KHjwNYX55M28eQocEzgih4nw4HJ0BkUATChtoQECKJOMy20QDgCxLUgHpDtoN4RHim0vYRjuMEchoDgNUT90LnpvGle7ZejyrdKg1vnptXei9wbbBk5t7fOt1hWfeJOa7MfOuXb1V-tUGfGcK21rTdAG_2G6Fxzp03tmmM6GzTfx5aYPzS-PDPtoqdRXMwVfdQ_Prq_lokkxvxzej4TTRKRFdUpZakiUvpJCalpIJxnKqQZY5oRkThJSpljxbSEFFzoEvGCwXqSApFxKEZnvoYi3b9ovaLIu4WjSgWm9r7d-U01b97TR2pR7cs8olzQXkUeD4S8C7pz7aULUNhakq3RjXB0VTnmacSM4ierpGC-9C8Kb8GUNAfQSkYkDqMyBFIeInazzemapH1_t4oPAfe_Tbxo_wd3rsHUc2mR4</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Calcagno, Andrea</creator><creator>Dal Conte, Ivano</creator><creator>Cattaneo, Dario</creator><creator>Testi, Roberto</creator><creator>Mistrangelo, Massimiliano</creator><creator>Gervasoni, Cristina</creator><creator>de Nicolò, Amedeo</creator><creator>Bonora, Stefano</creator><creator>D'Avolio, Antonio</creator><creator>Di Perri, Giovanni</creator><general>American Society for Microbiology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2534-8815</orcidid><orcidid>https://orcid.org/0000-0002-1321-4126</orcidid></search><sort><creationdate>20210101</creationdate><title>Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders</title><author>Calcagno, Andrea ; Dal Conte, Ivano ; Cattaneo, Dario ; Testi, Roberto ; Mistrangelo, Massimiliano ; Gervasoni, Cristina ; de Nicolò, Amedeo ; Bonora, Stefano ; D'Avolio, Antonio ; Di Perri, Giovanni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a418t-ffa91d5c989a2f9383372a09f71263811f4a956b98287505b30db481458908a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral Agents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Calcagno, Andrea</creatorcontrib><creatorcontrib>Dal Conte, Ivano</creatorcontrib><creatorcontrib>Cattaneo, Dario</creatorcontrib><creatorcontrib>Testi, Roberto</creatorcontrib><creatorcontrib>Mistrangelo, Massimiliano</creatorcontrib><creatorcontrib>Gervasoni, Cristina</creatorcontrib><creatorcontrib>de Nicolò, Amedeo</creatorcontrib><creatorcontrib>Bonora, Stefano</creatorcontrib><creatorcontrib>D'Avolio, Antonio</creatorcontrib><creatorcontrib>Di Perri, Giovanni</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Calcagno, Andrea</au><au>Dal Conte, Ivano</au><au>Cattaneo, Dario</au><au>Testi, Roberto</au><au>Mistrangelo, Massimiliano</au><au>Gervasoni, Cristina</au><au>de Nicolò, Amedeo</au><au>Bonora, Stefano</au><au>D'Avolio, Antonio</au><au>Di Perri, Giovanni</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>65</volume><issue>1</issue><issn>0066-4804</issn><eissn>1098-6596</eissn><abstract>Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>33106270</pmid><doi>10.1128/AAC.01902-20</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-2534-8815</orcidid><orcidid>https://orcid.org/0000-0002-1321-4126</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0066-4804
ispartof Antimicrobial agents and chemotherapy, 2021-01, Vol.65 (1)
issn 0066-4804
1098-6596
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7927807
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Antiviral Agents
title Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T10%3A44%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20Tenofovir%20Plasma%20Exposure%20in%20HIV%20Oral%20Pre-exposure%20Prophylaxis%20Recipients%20with%20Gastrointestinal%20Disorders&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Calcagno,%20Andrea&rft.date=2021-01-01&rft.volume=65&rft.issue=1&rft.issn=0066-4804&rft.eissn=1098-6596&rft_id=info:doi/10.1128/AAC.01902-20&rft_dat=%3Cproquest_pubme%3E2454651953%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2454651953&rft_id=info:pmid/33106270&rfr_iscdi=true